环球医疗(02666)公布，公司的全资附属公司通用环球国际融资租赁(天津)有限公司已决定向中国境内的 机构投资者发行本金总额最高达人民币2亿元的2025年第一期境内中期票据，第一期票据为期二年，利 率为固定利率，并将于截止认购申请时通过簿记建档方式最终厘定。发行第一期票据的净额收益将由发 行人用作偿还到期债务。 ...

智通财经APP讯，环球医疗(02666)公布，公司的全资附属公司通用环球国际融资租赁(天津)有限公司已 决定向中国境内的机构投资者发行本金总额最高达人民币2 亿元的2025年第一期境内中期票据，第一期 票据为期二年，利率为固定利率，并将于截止认购申请时通过簿记建档方式最终厘定。发行第一期票据 的净额收益将由发行人用作偿还到期债务。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承 擔任何責任。 通用環球醫療集團有限公司 GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED （於香港註冊成立的有限公司） （股份代號：2666） 有關本公司的全資附屬公司 通用環球國際融資租賃（天津）有限公司 於中國發行第一期境內中期票據的公告 本公告乃由通用環球醫療集團有限公司（「本公司」）根據香港聯合交易所有限公司證券上 市規則（「上市規則」）第13.09(2)(a)條及香港法例第571章證券及期貨條例第XIVA部內幕 消息條文（定義見上市規則）作出。 本公司的全資附屬公司通用環球國際融資租賃（天津）有限公司（「發行人」）於中國銀行 間市場交易商協會註冊在中華人民共和國（「中國」）發行本金總額最高達人民幣 10 億元的 境內中期票據，截至本公告日期剩餘額度為人民幣 10 億元。 發行人已決定向中國境內的機構投資者發行本金總額最高達人民幣 2 億元的二零二五年第一 期境 ...

通用环球医疗集团有限公司（原名：环球医疗金融与技术咨询服务有限公司）是一家从事医疗健康业务 的中国公司。该公司主要通过两个分部运营。金融业务分部主要包括直接融资租赁、售后回租赁、保 理、经营租赁和咨询服务。医疗健康业务主要包括医疗健康服务、医院运营管理和医疗设备进出口贸易 和国内贸易、设备全周期管理和医疗数字科技服务。该公司主要在中国境内开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-11-05 | 4.45亿 | 185.45万 | 0.42% | | 2025-11-04 | 4.43 Z | -249.85万 | -0.56% | | 2025-11-03 | 4.45 Z | 142.90万 | 0.32% | | 2025-10-31 | 4.44亿 | 197.70万 | 0.45% | | 2025-10-30 | 4.42亿 | -36.60万 | -0.08% | 证券 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 通用環球醫療集團有限公司 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 不適用 備註： 因公司註冊成立於香港，故法定股本及註冊股本的概念並不適用。 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02666 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,891,539,661 | | 0 | | 1,891,539,661 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 1 ...

通用环球医疗集团有限公司（原名：环球医疗金融与技术咨询服务有限公司）是一家从事医疗健康业务 的中国公司。该公司主要通过两个分部运营。金融业务分部主要包括直接融资租赁、售后回租赁、保 理、经营租赁和咨询服务。医疗健康业务主要包括医疗健康服务、医院运营管理和医疗设备进出口贸易 和国内贸易、设备全周期管理和医疗数字科技服务。该公司主要在中国境内开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-11-04 | 4.43亿 | -249.85万 | -0.56% | | 2025-11-03 | 4.45 Z | 142.90万 | 0.32% | | 2025-10-31 | 4.44亿 | 197.70万 | 0.45% | | 2025-10-30 | 4.42亿 | -36.60万 | -0.08% | | 2025-10-28 | 4.4217 | -243.25万 | -0.55% | ...

Group 1 - The core viewpoint of the report is that Pacific Securities maintains a "Buy" rating for Universal Medical (02666.HK), forecasting significant revenue and profit growth from 2025 to 2027, with projected revenues of 14.72 billion, 15.34 billion, and 16.25 billion yuan, and net profits of 2.12 billion, 2.23 billion, and 2.37 billion yuan respectively [1] - The expected EPS for the same period is 1.12, 1.18, and 1.25 yuan, with corresponding PE valuations of 4.99, 4.75, and 4.47 times based on the closing price on October 29 [1] - The company’s healthcare business is identified as a core growth engine, while its financial business remains stable with effective risk control, enhancing the overall value of the company [1] Group 2 - Universal Medical has a market capitalization of 11.576 billion HKD, ranking 5th in the healthcare services II industry [2] - Key performance indicators show a ROE of 12.39%, a net profit margin of 17.61%, and a debt ratio of 73.38%, which are competitive compared to the industry averages [2] - The company’s revenue of 14.701 billion HKD is significantly higher than the industry average of 3.832 billion HKD, indicating strong market positioning [2]

智通财经APP获悉，太平洋证券发布研报称，维持环球医疗(02666)"买入"评级，预计2025-2027年公司 营业收入为147.23、153.43、162.54亿元，归母净利润为21.18、22.28、23.66亿元，EPS为1.12、1.18、 1.25元，对应10月29日收盘价的PE估值为4.99、4.75、4.47倍。看好公司医疗健康业务高速增长带来的 估值提升，给予2025年6.5倍PE估值，对应目标价7.97港元。公司医疗健康业务成为核心增长引擎，金 融业务保持稳健且风控成效显著，两大业务板块协同效应持续夯实公司价值。 事件：环球医疗发布2025年半年度报告。报告期内，公司实现收入75.81亿元，同比+15.9%;实现期内溢 利13.35亿元，同比+6.6%;实现普通股权益持有人应占期内溢利12.28亿元，同比+8.0%。 太平洋证券主要观点如下： 公司经营业绩延续稳健增长态势 截至2025H1，公司基本每股收益0.65元，同比+8.0%;股本回报率为14.08%，总资产回报率为3.11%。从 收入结构看，医疗健康业务2025H1实现收入49.64亿元，占总营收比重提升至65.5%，同比+27.7 ...

Core Viewpoint - Pacific Securities maintains a "Buy" rating for Universal Medical (02666), projecting revenue growth from 147.23 billion to 162.54 billion CNY and net profit growth from 21.18 billion to 23.66 billion CNY from 2025 to 2027, with an estimated PE ratio decreasing from 4.99 to 4.47 times [1] Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of 75.81 billion CNY, a year-on-year increase of 15.9%, and a profit of 13.35 billion CNY, up 6.6% [1] - Basic earnings per share for 2025H1 were 0.65 CNY, reflecting an 8.0% increase year-on-year, with a return on equity of 14.08% and a return on total assets of 3.11% [1] - The medical health segment generated 49.64 billion CNY in revenue, accounting for 65.5% of total revenue, with a year-on-year growth of 27.7% [2] Group 2: Medical Health Business - The medical health segment is the core growth driver, with significant contributions from three areas: 1. Comprehensive medical services with 65 hospitals and over 16,000 beds, despite a 14.6% decline in profit to 2.31 billion CNY due to external pressures [2] 2. Specialized medical services, including the acquisition of Shandong University of Traditional Chinese Medicine Affiliated Eye Hospital [2] 3. Health technology revenue reached 6.46 billion CNY, a remarkable 142.1% increase, managing assets worth 370 billion CNY across over 1,600 institutions [2] Group 3: Financial Business - The financial business, focusing on medical financing leasing, generated 28.51 billion CNY in revenue, a 6.9% increase year-on-year [3] - The financial segment's non-performing asset ratio was 0.97%, with a provision coverage ratio of 313.87%, indicating strong risk management capabilities [3] - The average cost of interest-bearing liabilities decreased by 44 basis points to 3.40%, enhancing both risk resistance and cost control [3]

Group 1 - The core viewpoint of the article highlights that Universal Medical (02666.HK) has shown stable growth in its overall operations, with positive results in key areas as of the first three quarters of 2025 [1] - For the nine months ending September 30, 2025, the group's revenue increased by approximately 12.8% compared to the same period last year, while profit rose by about 7.6% [1][1] - The profit attributable to ordinary shareholders increased by approximately 4.2% year-on-year [1] Group 2 - As of October 30, 2025, Universal Medical's stock closed at HKD 6.14, up 0.33%, with a trading volume of 5.4575 million shares and a turnover of HKD 33.4515 million [1] - Investment banks predominantly rate the stock as "Buy," with one bank issuing a "Buy" rating in the last 90 days [1] - Guosen Securities recently assigned an "Outperform" rating to Universal Medical [1] Group 3 - Universal Medical has a market capitalization of HKD 11.576 billion, ranking 5th in the Medical Services II industry [1] - Key performance indicators show a Return on Equity (ROE) of 12.39%, which is significantly higher than the industry average of -0.02% [1] - The company's operating revenue stands at HKD 14.701 billion, surpassing the industry average of HKD 3.832 billion, ranking 4th in the sector [1]